Key takeaway:
- Science Corporation’s PRIMA retinal implant received CE Mark approval in July 2026, making it commercially available across 30 European countries for geographic atrophy (GA) due to age-related macular degeneration (AMD).
- In the pivotal NEJM trial, patients gained a mean of 25.5 letters on an eye chart, and 84% could read letters, numbers, and words after the implant.
- PRIMA is not approved in the US yet. It holds FDA Breakthrough Device and Humanitarian Use Device designations, but still needs a Humanitarian Device Exemption to reach American patients.
- This is a meaningful moment for the retinal prosthesis category as a whole: the only prior commercially available device, Argus II, is no longer on the market.
Retinal prosthetics have had a quiet few years. The one device that made it to market, Argus II, is no longer available. PRIMA’s CE Mark approval changes that, and the data behind it is different enough from prior devices to be worth understanding in detail.
What the PRIMA System Is and How It Works
PRIMA is a subretinal photovoltaic implant, a 2×2mm chip with 378 light-powered pixels, surgically placed beneath the atrophic macula. It’s paired with a pair of camera-equipped glasses and a pocket processor.
Here’s the mechanism: the glasses capture a visual scene and project it onto the implant using near-infrared light. The photovoltaic pixels convert that light into electrical signals, which stimulate the retinal neurons that are still functioning beneath the damaged macula, creating a form of prosthetic central vision. The glasses also include a zoom function, letting patients magnify text.
This places PRIMA in the subretinal category of retinal prostheses, a design first developed for research use years ago and now advanced into a wireless, photovoltaic-powered commercial device.
What the European Approval Actually Covers
The CE Mark, issued by DEKRA under the EU Medical Device Regulation, authorizes commercial distribution across 30 European countries. It’s specifically for adults with severe central vision loss caused by geographic atrophy secondary to dry AMD, a condition affecting more than five million people globally.
Reimbursement applications and clinical site activation are underway across Europe, with the first commercial implantation expected in Germany. This isn’t full continent-wide patient access on day one, it’s regulatory clearance that opens the door, with individual countries still working through reimbursement.
Who This Treatment Is (and Isn’t) For
PRIMA targets a specific patient population, not vision loss broadly:
- Indicated for: Adults with geographic atrophy secondary to dry AMD, who have lost central vision but retain enough surviving retinal neurons for the implant to stimulate.
- Not currently indicated for: Other causes of vision loss. Science Corporation has stated it’s exploring additional indications, including Stargardt disease and other inherited retinal diseases like retinitis pigmentosa, but those aren’t approved uses yet.
- Not available in: The United States. PRIMA holds FDA Breakthrough Device designation (since 2023) and Humanitarian Use Device designation (granted July 2026), but commercial availability would require review and approval through a Humanitarian Device Exemption, a process with no confirmed timeline yet.
What the Clinical Trial Results Showed
The pivotal trial, published in the New England Journal of Medicine, evaluated the PRIMA system in 38 patients across 17 clinical sites in five countries. The results:
| Outcome | Result |
|---|---|
| Mean improvement on ETDRS letter chart | 25.5 letters (more than 5 lines) |
| Patients able to read letters, numbers, and words | 84% |
| Patients with significant visual acuity gain (≥10 letters) at 12 months | 80% (p<0.001) |
| Impact on existing natural vision | No decline observed |
The detail worth sitting with: this trial measured form vision, the ability to read letters and words, not just light or shape perception. That’s a materially different clinical bar than earlier-generation retinal prosthetics were evaluated against.
Why Argus II’s Discontinuation Matters Here
Argus II, an epiretinal (not subretinal) implant, was the only retinal prosthesis to reach commercial availability before PRIMA. It restored partial functional vision, primarily light and dark perception, object localization, and shape recognition, and was genuinely valuable for patients with advanced retinitis pigmentosa. But it did not restore the kind of detailed form vision needed to read.
Argus II is no longer on the market. PRIMA’s approval isn’t just one company hitting a regulatory milestone, it’s effectively re-establishing a commercially available option in a category that had gone quiet, with clinical data showing a meaningfully higher functional ceiling than the prior generation achieved.
What This Means for the Future of Retinal Prosthetics
A few implications worth watching:
- Reimbursement will determine real-world reach. CE Mark alone doesn’t guarantee patient access, country-by-country reimbursement decisions will shape how many patients actually receive the implant in year one.
- US timeline remains genuinely uncertain. The Humanitarian Device Exemption pathway exists for exactly this kind of rare-condition device, but there’s no confirmed date for US availability.
- Next-generation versions are already in development. Science Corporation has stated it’s working on higher-resolution implants and improved glasses with internal processing and eye tracking, aimed at expanding field of view and reducing complexity for patients.
- Other indications may follow. If geographic atrophy data holds up in real-world use, expansion into other retinal degenerations (like retinitis pigmentosa) is a stated company goal, not yet a regulatory reality.
Frequently Asked Questions
Is PRIMA available in the United States yet? No. It has FDA Breakthrough Device and Humanitarian Use Device designations, but still requires approval through a Humanitarian Device Exemption before it can be marketed in the US.
How is PRIMA different from Argus II? Argus II was an epiretinal implant that restored light perception and shape recognition. PRIMA is a subretinal photovoltaic implant, and its pivotal trial data shows patients regaining the ability to read letters, numbers, and words, a higher functional outcome than Argus II achieved. Argus II is also no longer commercially available.
What condition does PRIMA treat? Geographic atrophy secondary to dry age-related macular degeneration, a specific late-stage form of AMD affecting central vision.
Does the implant restore normal vision? No. It creates a form of prosthetic central vision sufficient for reading letters, numbers, and words in most trial patients, not full restoration of natural sight.
